1. Compared with irbesartan, there was a greater reduction in UP/C with sparsentan, and a larger proportion of patients achieved FPRE. The figure illustrates the reduction in UP/C from baseline to week 8 for (A) all sparsentan doses for the EES and (B) 400 and...
Compared with irbesartan, there was a greater reduction in UP/C with sparsentan, and a larger proportion of patients achieved FPRE. The figure illustrates the reduction in UP/C from baseline to week 8 for (A) all sparsentan doses for the EES and (B) 400 and 800 mg sparsentan doses for the EES. Reduction in UP/C from baseline to week 8 for (C) all sparsentan doses for the FAS and (D) 400 and 800 mg doses for the FAS. (E) Reduction in 24-hour urinary protein excretion for the EES. (F) Proportion of patients who achieved FPRE for the EES. *Geometric least squares mean percent change from baseline. P values for changes in UP/C from analysis of covariance. FPRE is defined as UP/C≤1.5 g/g and >40% reduction in UP/C. P value for FPRE obtained using the Fisher exact test. For the FAS analysis, patients with a missing UP/C value were imputed as zero. EES, efficacy evaluable set; FAS, full analysis set; FPRE, FSGS partial remission endpoint; FSGS, focal segmental glomerulosclerosis; UP/C, urinary protein-to-creatinine ratio.
Howard Trachtman et al. JASN 2018;29:
©2018 by American Society of Nephrology